ReviewAdvanced drug delivery reviews2016
Imaging-guided delivery of RNAi for anticancer treatment.
Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 113 citations in OpenAlex.
- Recent advances of metal-organic frameworks (MOFs) for drug delivery, cancer imaging and theranostics.Theranostics · 2026Review
- Design of therapeutic siRNAs for potential application to infection with chikungunya virus.Heliyon · 2025Article
- Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025Review
- Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy.Chemical & biomedical imaging · 2024Review
- Review
- Nanotechnology-enabled gene delivery for cancer and other genetic diseases.Expert opinion on drug delivery · 2023Review
- Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.Journal of oncology · 2022Review
- RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer.Pharmaceutics · 2021Review
- Peptide Nanoparticle-Mediated Combinatorial Delivery of Cancer-Related siRNAs for Synergistic Anti-Proliferative Activity in Triple Negative Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- [DJ-1 alleviates oxidative stress injury by activating the Nrf2 pathway in rats with cerebral ischemia-reperfusion injury].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Current Advances in Black Phosphorus-Based Drug Delivery Systems for Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Insight Into the Prospects for RNAi Therapy of Cancer.Frontiers in pharmacology · 2021Review
- Tumor necrosis factor-α small interfering RNA alveolar epithelial cell-targeting nanoparticles reduce lung injury in C57BL/6J mice with sepsis.The Journal of international medical research · 2021Article
- Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors.Frontiers in chemistry · 2020Review
- Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics.Theranostics · 2020Review
- Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases.Drug discovery today · 2019Review
- Exploiting Nanomaterial-mediated Autophagy for Cancer Therapy.Small methods · 2019Article
- RNA-silencing nanoprobes for effective activation and dynamic imaging of neural stem cell differentiation.Theranostics · 2019Article
- Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer.Nanotheranostics · 2019Article
- Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
The RNA interference (RNAi) technique is a new modality for cancer therapy, and several candidates are being tested clinically. In the development of RNAi-based therapeutics, imaging methods can provide a visible and quantitative way to investigate the therapeutic effect at anatomical, cellular, and molecular level; to noninvasively trace the distribution; to and study the biological processes in preclinical and clinical stages. Their abilities are important not only for therapeutic optimization and evaluation but also for shortening of the time of drug development to market. Typically, imaging-functionalized RNAi therapeutics delivery that combines nanovehicles and imaging techniques to study and improve their biodistribution and accumulation in tumor site has been progressively integrated into anticancer drug discovery and development processes. This review presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. Finally, we focus on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.